ATE350386T1 - Elk ligand, ein cytokin - Google Patents

Elk ligand, ein cytokin

Info

Publication number
ATE350386T1
ATE350386T1 AT94902233T AT94902233T ATE350386T1 AT E350386 T1 ATE350386 T1 AT E350386T1 AT 94902233 T AT94902233 T AT 94902233T AT 94902233 T AT94902233 T AT 94902233T AT E350386 T1 ATE350386 T1 AT E350386T1
Authority
AT
Austria
Prior art keywords
elk
cytokine
polypeptides
ligand
elk ligand
Prior art date
Application number
AT94902233T
Other languages
English (en)
Inventor
Stewart Lyman
M Patricia Beckmann
Peter R Baum
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE350386T1 publication Critical patent/ATE350386T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Silicon Polymers (AREA)
  • Polyurethanes Or Polyureas (AREA)
AT94902233T 1992-11-13 1993-11-15 Elk ligand, ein cytokin ATE350386T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97769392A 1992-11-13 1992-11-13

Publications (1)

Publication Number Publication Date
ATE350386T1 true ATE350386T1 (de) 2007-01-15

Family

ID=25525421

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94902233T ATE350386T1 (de) 1992-11-13 1993-11-15 Elk ligand, ein cytokin

Country Status (12)

Country Link
US (6) US5512457A (de)
EP (1) EP0669929B1 (de)
JP (1) JP3560609B2 (de)
AT (1) ATE350386T1 (de)
AU (1) AU669960B2 (de)
CA (1) CA2148484A1 (de)
DE (1) DE69334100T2 (de)
DK (1) DK0669929T3 (de)
ES (1) ES2279508T3 (de)
NZ (1) NZ258697A (de)
PT (1) PT669929E (de)
WO (1) WO1994011384A1 (de)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590030B1 (de) * 1991-06-21 2004-09-29 The Walter and Eliza Hall Institute of Medical Research Neuartige rezeptor-typ tyrosinkinase und deren verwendung
JP3560609B2 (ja) * 1992-11-13 2004-09-02 イミュネックス・コーポレーション Ｅｌｋリガンドと呼ばれる新規なサイトカイン
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
IL113252A0 (en) * 1994-04-04 1995-07-31 Regeneration Pharmaceuticals I Eph receptors binding ligands
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5624899A (en) * 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
USRE37582E1 (en) 1994-10-05 2002-03-12 Immunex Corporation Cytokine designated LERK-6
PT785716E (pt) 1994-10-05 2007-02-28 Immunex Corp Citóquina designada por lerk-6
WO1996013518A1 (en) * 1994-10-27 1996-05-09 Genentech, Inc. Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor
US5759775A (en) 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US6537773B1 (en) * 1995-06-07 2003-03-25 The Institute For Genomic Research Nucleotide sequence of the mycoplasma genitalium genome, fragments thereof, and uses thereof
JPH11514238A (ja) * 1995-10-25 1999-12-07 リジェネロン ファーマシューティカルズ，インコーポレイテッド 生物学的に活性なｅｐｈファミリーリガンド
US6610296B2 (en) 1995-10-26 2003-08-26 Genentech, Inc. Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
CA2259157A1 (en) * 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
US5874268A (en) 1996-09-23 1999-02-23 Duke University Method of introducing exogenous compounds into cells by electroporation and apparatus for same
AU9594598A (en) 1997-10-02 1999-04-27 Millennium Pharmaceuticals, Inc. Modulation of lerk-2-mediated cell adhesion
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
US6608172B1 (en) * 2000-06-09 2003-08-19 Good Biotech Corporation Isolation of IgY (ΔFc) antibodies
AU2002212292A1 (en) * 2000-09-29 2002-04-08 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
US8173783B2 (en) * 2000-12-08 2012-05-08 Good Biotech Corporation Process for selectively isolating IgY antibodies from egg yolk of an anseriform bird and IgY antibodies obtained thereby
US6680376B2 (en) 2000-12-08 2004-01-20 Good Biotech Corporation Process for selectively isolating avian immunoglobulins
WO2002055694A2 (en) * 2001-01-16 2002-07-18 Genset Sa Discriminative nucleic acid analysis using clone sequence signatures
US20030096774A1 (en) * 2001-11-21 2003-05-22 Igor Gonda Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
DE60234713D1 (de) * 2001-12-18 2010-01-21 Endocube Sas Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind
US7858297B2 (en) * 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
AU2003259995B2 (en) 2002-08-28 2009-07-02 Immunex Corporation Compositions and methods for treating cardiovascular disease
WO2004028551A1 (en) * 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
AU2004230539A1 (en) * 2003-04-11 2004-10-28 Medimmune, Llc EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
US20050059592A1 (en) * 2003-04-11 2005-03-17 Kiener Peter A. EphA2 and hyperproliferative cell disorders
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
MXPA05013565A (es) * 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
KR101254371B1 (ko) 2003-07-18 2013-05-02 암젠 프레몬트 인코포레이티드 간세포 성장인자에 결합하는 분리된 항체
EP1648935A2 (de) 2003-07-25 2006-04-26 Amgen Inc. Antagonisten und agonisten von ldcam und anwendungsverfahren
WO2006081418A2 (en) * 2005-01-27 2006-08-03 The Burnham Institute Ephb receptor-binding peptides
JPWO2007043629A1 (ja) * 2005-10-05 2009-04-16 アキュメンバイオファーマ株式会社 エフリンｂ２を用いる血管新生の抑制方法
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
ES2650224T3 (es) 2007-08-21 2018-01-17 Amgen, Inc. Proteínas de unión al antígeno C-FMS humano
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
CN103703000B (zh) 2011-03-23 2015-11-25 安姆根有限公司 Cdk4/6和flt3的稠合三环双重抑制剂
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2014036022A1 (en) 2012-08-29 2014-03-06 Amgen Inc. Quinazolinone compounds and derivatives thereof
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
UA126115C2 (uk) 2016-03-08 2022-08-17 Янссен Байотек, Інк. Антитіло до gitr
US20190292254A1 (en) 2016-07-14 2019-09-26 Scholar Rock, Inc. TGFBeta Antibodies, Methods and Uses
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
MA50077A (fr) 2017-09-08 2020-07-15 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
ES2995514T3 (en) 2018-05-04 2025-02-10 Amgen Inc Kras g12c inhibitors and methods of using the same
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3790886B1 (de) 2018-05-10 2024-06-26 Amgen Inc. Kras g12c-inhibitoren zur behandlung von krebs
ES2938987T3 (es) 2018-06-01 2023-04-18 Amgen Inc Inhibidores de KRAS G12c y métodos de uso de los mismos
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES3060664T3 (en) 2018-06-12 2026-03-27 Amgen Inc Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
TWI844602B (zh) 2018-12-20 2024-06-11 美商安進公司 Kif18a抑制劑
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
EP3898616B1 (de) 2018-12-20 2024-10-02 Amgen Inc. Als kif18a-inhibitoren verwendbare heteroarylamide
JP7676308B2 (ja) 2018-12-20 2025-05-14 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
EP3738593A1 (de) 2019-05-14 2020-11-18 Amgen, Inc Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms
EP4007756B1 (de) 2019-08-02 2025-12-24 Amgen Inc. Kif18a-inhibitoren
US12540129B2 (en) 2019-08-02 2026-02-03 Amgen Inc. KIF18A inhibitors
AU2020326627B2 (en) 2019-08-02 2026-01-29 Amgen Inc. KIF18A inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
EP4031542B1 (de) 2019-09-18 2025-10-15 Merck Sharp & Dohme LLC Kleinmolekülige inhibitoren der kras-g12c-mutante
EP4684786A3 (de) 2019-10-24 2026-04-08 Amgen Inc. Pyridopyrimidinderivate als kras-g12c- und kras-g12d-hemmer bei der behandlung von krebs
CN114867726B (zh) 2019-10-28 2023-11-28 默沙东有限责任公司 Kras g12c突变体的小分子抑制剂
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
CN120699039A (zh) 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
TW202128688A (zh) 2019-11-08 2021-08-01 美商銳新醫藥公司 雙環雜芳基化合物及其用途
JP2023501528A (ja) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
EP4065231A1 (de) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Kovalente ras-inhibitoren und verwendungen davon
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
CN114929279A (zh) 2020-01-07 2022-08-19 锐新医药公司 Shp2抑制剂给药和治疗癌症的方法
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
EP4183395A4 (de) 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. Pyrimidinverbindung enthaltende kombination zur verwendung bei der tumorbehandlung
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
US20240051956A1 (en) 2020-12-22 2024-02-15 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022250170A1 (en) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023064058A1 (en) 2021-10-12 2023-04-20 Peloton Therapeutics Inc. Tricyclic sultams and sulfamides as antitumor agents
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
WO2023172858A1 (en) 2022-03-07 2023-09-14 Amgen Inc. A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2023358792A1 (en) 2022-10-14 2025-04-17 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
EP4687905A1 (de) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Zusammensetzungen zur induzierung der ras-gtp-hydrolyse und verwendungen davon
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
KR20260042550A (ko) 2023-08-24 2026-03-31 다이호야쿠힌고교 가부시키가이샤 세다주리딘 및 아자시티딘의 고정 용량 조합물
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
TW202542151A (zh) 2023-12-22 2025-11-01 美商銳格醫藥有限公司 Ｓｏｓ１抑制劑及其用途
TW202602929A (zh) 2024-03-21 2026-01-16 美商思進公司 Ｃｄ２５抗體、抗體-藥物共軛體及彼等之用途
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134121A (en) * 1988-03-28 1992-07-28 Regents Of The University Of California Nerve growth factor peptides
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
US5571674A (en) * 1989-09-18 1996-11-05 The Trustees Of Columbia University In The City Of New York DNA oligomers for use in detection of campylobacter pylori and methods of using such DNA oligomers
AU7579991A (en) * 1990-02-20 1991-09-18 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
IE911318A1 (en) * 1990-04-23 1991-10-23 Yeda Res & Dev Use of a tumor necrosis factor for facilitating nerve¹regeneration
WO1992007094A1 (en) * 1990-10-16 1992-04-30 The Regents Of The University Of Michigan Cytokine-induced marker for inflammatory response
DE69229598T2 (de) * 1991-04-19 1999-11-04 Children's Medical Center Corp., Boston Verfahren zur vorbeugung nmda-rezeptorkomplex-vermittelter neuronaler schäden
EP0590030B1 (de) * 1991-06-21 2004-09-29 The Walter and Eliza Hall Institute of Medical Research Neuartige rezeptor-typ tyrosinkinase und deren verwendung
US5652355A (en) * 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
CA2149333C (en) * 1992-11-13 2002-01-22 Timothy D. Bartley Eck receptor ligands
JP3560609B2 (ja) * 1992-11-13 2004-09-02 イミュネックス・コーポレーション Ｅｌｋリガンドと呼ばれる新規なサイトカイン
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek

Also Published As

Publication number Publication date
JP3560609B2 (ja) 2004-09-02
NZ258697A (en) 1996-03-26
CA2148484A1 (en) 1994-05-26
DE69334100D1 (de) 2007-02-15
US6540992B1 (en) 2003-04-01
AU669960B2 (en) 1996-06-27
PT669929E (pt) 2007-04-30
US20040022767A1 (en) 2004-02-05
DE69334100T2 (de) 2007-07-19
US5670625A (en) 1997-09-23
EP0669929B1 (de) 2007-01-03
DK0669929T3 (da) 2007-01-29
ES2279508T3 (es) 2007-08-16
US5512457A (en) 1996-04-30
EP0669929A4 (de) 1997-01-15
AU5667594A (en) 1994-06-08
WO1994011384A1 (en) 1994-05-26
EP0669929A1 (de) 1995-09-06
JPH08503368A (ja) 1996-04-16
US5728813A (en) 1998-03-17
US5627267A (en) 1997-05-06

Similar Documents

Publication Publication Date Title
ATE350386T1 (de) Elk ligand, ein cytokin
ATE259377T1 (de) An den zelloberflächenrezeptor hek bindendes cytokin
ATE353906T1 (de) Cd27 ligand
DK0770088T3 (da) Hidtil ukendt cytokin betegner LERK-5.
DK0871702T3 (da) Cytokin betegnet Lerk-7
CA2312667A1 (en) Novel cytokine
DE69738432D1 (de) Targeting von adenoviren mit hilfe von konformationsbeschränkten peptidmotiven
DE69232537D1 (de) Rezeptoren der steroid/thyroid superfamilie von rezeptoren
DE69535719D1 (de) Fas-antigenbindender ligand
EA199900869A1 (ru) Цитокин-подобный фактор 7 млекопитающих
NZ238056A (en) Surface protein of metastasis forming tumour cells, related polypeptides, dna encoding these, antibodies, assays and pharmaceuticals
WO2001025438A3 (en) Ifn-alpha homologues
NO984233L (no) Cytokin kalt lerk-8
MX9700213A (es) Citocina novedosa designada como lerk-5.
EA199900663A1 (ru) Новые белки, связывающиеся с рецептором 1 интерферона, кодирующая их днк и способы модуляции клеточного ответа на интерфероны
ATE81591T1 (de) Interleukin-2 induziertes antineoplastisches peptid.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0669929

Country of ref document: EP

REN Ceased due to non-payment of the annual fee